Sarah Jaw‐Tsai

Rociletinib in <i>EGFR</i>-Mutated Non–Small-Cell Lung Cancer

Lecia V. Sequist, Jean‐Charles Soria, Jonathan W. Goldman et al. · New England Journal of Medicine · 2015 · 660 citations · Full text

Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC

Annette O. Walter, Robert Tjin Tham Sjin, Henry J. Haringsma et al. · Cancer Discovery · 2013 · 622 citations · Full text

First-in-human evaluation of CO-1686, an irreversible, highly selective tyrosine kinase inhibitor of mutations of EGFR (activating and T790M).

Lecia V. Sequist, Jean‐Charles Soria, Shirish M. Gadgeel et al. · Journal of Clinical Oncology · 2014 · 143 citations

Pathology, Pharmacotherapy, T790m Mutation +21

Antiparkinsonian Actions of CP-101,606, an Antagonist of NR2B Subunit-Containing N-Methyl-d-Aspartate Receptors

Kathy Steece‐Collier, Leslie K. Chambers, Sarah Jaw‐Tsai et al. · Experimental Neurology · 2000 · 136 citations

Biochemistry, Functional Selectivity, Medicine +7

A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours

Richard H. Wilson, TR Jeffry Evans, Mark R. Middleton et al. · British Journal of Cancer · 2017 · 76 citations · Full text